Molenda Sara, Deptuch Tomasz, Sikorska Agata, Lorenc Patryk, Smialek Maciej Jerzy, Florczak-Substyk Anna, Pawlak Piotr, Dams-Kozlowska Hanna
Department of Cancer Immunology, Poznan University of Medical Sciences, Poznan, Poland.
Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland.
Int J Nanomedicine. 2025 Jun 23;20:8023-8039. doi: 10.2147/IJN.S519906. eCollection 2025.
Oligonucleotide-based drugs, such as siRNA, hold great promise for disease treatment, including cancer. However, their clinical application has challenges related to cell-specific delivery and susceptibility to degradation. The use of drug delivery systems (DDS) may address these problems. Nanoparticles of bioengineered spider silk demonstrate significant potential as DDS due to their biocompatibility and biodegradability. Another advantage of this material is the possibility of functionalization, which allows the control of its property. The main objective of this study was to develop a strategy for targeted delivery of oligonucleotide-based therapeutics into cancer cells using bioengineered silk technology.
Two spider silk spheres that bind oligonucleotides and target cancer cells that overexpress HER2 (HER2+) were constructed. One type of sphere was made of a newly designed silk, H2.1MS1KN, which contained two functional peptides: H2.1 for binding HER2 and KN for binding oligonucleotide. The second type of sphere was formed of a blend of two previously described proteins, H2.1MS1 and MS2KN; these proteins differed not only in the functional domain (H2.1 vs KN) but also in the sequence of silk (MS1 vs MS2). The ability of proteins to bind oligonucleotides was analyzed via gel electrophoresis. The biophysicochemical properties of particles were analyzed using an SEM, NanoSight, ZetaSizer, flow cytometry, and scanning confocal microscopy. The silk particle potential was analyzed using siRNA for silencing expression in the HER2+ breast cancer model.
Both H2.1MS1KN and H2.1MS1:MS2KN proteins efficiently bound nucleic acid. H2.1MS1:MS2KN formed smaller spheres than H2.1MS1KN. Although both H2.1MS1KN and blended H2.1MS1:MS2KN spheres were effectively loaded with oligonucleotides, only H2.1MS1:MS2KN spheres delivered siRNA to HER2+ cancer cells that successfully silenced expression.
Not only the selection of functional peptides but also their quantity and type of silk is crucial when developing an effective silk-based DDS for delivering active siRNA.
基于寡核苷酸的药物,如小干扰RNA(siRNA),在包括癌症在内的疾病治疗方面具有巨大潜力。然而,它们的临床应用面临与细胞特异性递送和易降解性相关的挑战。使用药物递送系统(DDS)可能解决这些问题。生物工程蜘蛛丝纳米颗粒因其生物相容性和生物可降解性而显示出作为药物递送系统的巨大潜力。这种材料的另一个优点是可以进行功能化,从而能够控制其性能。本研究的主要目的是利用生物工程丝技术开发一种将基于寡核苷酸的治疗药物靶向递送至癌细胞的策略。
构建了两种结合寡核苷酸并靶向过表达人表皮生长因子受体2(HER2)的癌细胞(HER2+)的蜘蛛丝球体。一种球体由新设计的丝H2.1MS1KN制成,其包含两种功能肽:用于结合HER2的H2.1和用于结合寡核苷酸的KN。第二种球体由两种先前描述的蛋白质H2.1MS1和MS2KN的混合物形成;这些蛋白质不仅在功能域(H2.1与KN)不同,而且在丝的序列(MS1与MS2)上也不同。通过凝胶电泳分析蛋白质结合寡核苷酸的能力。使用扫描电子显微镜(SEM)、纳米粒度分析仪(NanoSight)、zeta电位分析仪(ZetaSizer)、流式细胞仪和扫描共聚焦显微镜分析颗粒的生物物理化学性质。在HER2+乳腺癌模型中使用siRNA分析丝颗粒沉默基因表达的潜力。
H2.1MS1KN和H2.1MS1:MS2KN蛋白质均能有效结合核酸。H2.1MS1:MS2KN形成的球体比H2.1MS1KN小。尽管H2.1MS1KN和混合的H2.1MS1:MS2KN球体都能有效地负载寡核苷酸,但只有H2.1MS1:MS2KN球体将siRNA递送至HER2+癌细胞并成功沉默基因表达。
在开发用于递送活性siRNA的有效丝基药物递送系统时,不仅功能肽的选择,而且丝的数量和类型都至关重要。